We are live on ! Find out more
CALA

Calithera Biosciences, Inc

Delisted

CALA was delisted on the 1st of February, 2023.

55 hedge funds and large institutions have $27M invested in Calithera Biosciences, Inc in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 19 increasing their positions, 16 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

329% more call options, than puts

Call options by funds: $236K | Put options by funds: $55K

19% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 16

17% less funds holding

Funds holding: 6655 (-11)

47% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 19

73% less capital invested

Capital invested by funds: $100M → $27M (-$72.9M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
55
Holders Change
-11
Holders Change %
-16.67%
% of All Funds
0.85%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
10
Increased
19
Reduced
16
Closed
19
Calls
$236K
Puts
$55K
Net Calls
+$181K
Net Calls Change
-$719K
Name Holding Trade Value Shares
Change
Change in
Stake
Primecap Management
1
Primecap Management
California
$7.14M +$156K +6,215 +1%
BI
2
BVF Inc
California
$4.96M
Citadel Advisors
3
Citadel Advisors
Florida
$2.35M +$3.1M +123,498 +234%
Vanguard Group
4
Vanguard Group
Pennsylvania
$1.9M -$93.9K -3,735 -3%
BlackRock
5
BlackRock
New York
$1.28M -$776K -30,888 -24%
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
$1.23M +$2.14M +85,041 +1,091%
D.E. Shaw & Co
7
D.E. Shaw & Co
New York
$1.01M +$1.84M +73,331 +2,824%
Renaissance Technologies
8
Renaissance Technologies
New York
$903K +$1.23M +48,940 +259%
Two Sigma Advisers
9
Two Sigma Advisers
New York
$799K +$1.4M +55,795 +1,317%
Two Sigma Investments
10
Two Sigma Investments
New York
$654K +$984K +39,145 +391%
Assenagon Asset Management
11
Assenagon Asset Management
Luxembourg
$501K -$126 -5 -0%
Jacobs Levy Equity Management
12
Jacobs Levy Equity Management
New Jersey
$480K +$204K +8,136 +29%
AFM
13
Anson Funds Management
Texas
$427K +$806K +32,063 New
Geode Capital Management
14
Geode Capital Management
Massachusetts
$383K -$286K -11,390 -28%
JP Morgan Chase
15
JP Morgan Chase
New York
$364K +$212K +8,420 +44%
Millennium Management
16
Millennium Management
New York
$347K -$273K -10,862 -29%
Dimensional Fund Advisors
17
Dimensional Fund Advisors
Texas
$317K -$678K -26,966 -53%
TCMG
18
TSP Capital Management Group
New Jersey
$233K
GCP
19
GSA Capital Partners
United Kingdom
$195K -$292K -11,625 -44%
VF
20
Virtu Financial
New York
$154K +$269K +10,721 +1,206%
SCM
21
Silverarc Capital Management
Massachusetts
$146K +$42.2K +1,678 +18%
State Street
22
State Street
Massachusetts
$144K
Morgan Stanley
23
Morgan Stanley
New York
$143K +$221K +8,803 +452%
BCM
24
Bridgeway Capital Management
Texas
$122K -$188K -7,500 -45%
Northern Trust
25
Northern Trust
Illinois
$102K -$377 -15 -0.2%

CALA Hedge Fund Activity: Q4 2021 in Review

55 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Calithera Biosciences, Inc (CALA) for Q4 2021, worth a combined $27M — down 73% from $100M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of CALA and 10 opened new positions — a net loss of 9 holders — while 16 trimmed existing stakes and 19 added.

The largest buyer was Citadel Advisors, adding an estimated $3.1M. The largest seller was Federated Hermes, cutting an estimated $8.38M.

  • 55 institutional investors held Calithera Biosciences, Inc (CALA) as of Q4 2021, down from 66 in Q3 2021.
  • Funds reported $27M of Calithera Biosciences, Inc stock for Q4 2021, down 73% quarter-over-quarter.
  • 10 funds opened new Calithera Biosciences, Inc positions in Q4 2021 and 19 closed out, a net change of -9 holders.
  • The largest Calithera Biosciences, Inc buyer in Q4 2021 was Citadel Advisors, an estimated $3.1M added.
  • The largest Calithera Biosciences, Inc seller in Q4 2021 was Federated Hermes, an estimated $8.38M sold.

Based on aggregated 13F filings for Q4 2021.